



Special points of interest for Primary Care

- Nalmefene - see page 3, awaiting guidance re: counselling

SMC advice:

- Atomoxetine (Strattera®)
- Axitinib (Inlyta®)
- Bosutinib (Bosulif®)
- Canakinumab (Ilaris®)
- Enzalutamide 40mg soft capsules (Xtandi®)
- Lapatinib (Tyverb®)
- Ondansetron (Setofilm®)
- Ranibizumab (Lucentis®)
- Sodium phenylbutyrate (Pheburane®)

Inside this issue :

Specialist lists - progress	1
Drug Safety Updates	1
SMC Advice issued in November 2013	2-3
Updates from previous SMC Advice	3
TAF Updates	4
SMC Briefing Note	4
Forthcoming SMC Advice	4



Specialist lists - progress

The Parkinson's disease specialist formulary list has been finalised. This list includes medicines that may be prescribed in General Practice, under the direction of a specialist.

Additions to the formulary include: apomorphine; domperidone for postural hypotension associated with dopamine agonists (particularly apomorphine); amantadine; and trihexyphenidyl hydrochloride (benzhexol).

New medicines added to the formulary from this list will not be incorporated into the current core formulary, but will be included in the formulary once launched on the new netFormulary platform.

The [Parkinson's disease specialist formulary list](#) can currently be accessed as with other specialist lists from the [Tayside Area Formulary](#) website.



Supply problems-tiotropium HandiHaler®

There is a manufacturing problem with tiotropium HandiHaler® (and the refill pack) and stock is currently limited across the hospitals in NHS Tayside. There is no timescale to when this will be resolved.

In the interim the following has been approved by the Respiratory team in Tayside:

- Start new patients on glycopyrronium inhaler (Sevair®) 44micrograms - once daily for inhalation
- Only switch current patients from tiotropium glycopyrronium inhaler if no stock of tiotropium HandiHaler®

Li... tro... v... alHaler® glycopyrronium is a powder for inhalation presented in a hard... which is... tered using the Breezhaler® device.

If for... eas... patients cannot tolerate / use glycopyrronium, then our next choice is aclidinium (122micrograms twice daily) which is available as a dry powder inhaler via the Genuair® device.

Please note: tiotropium Respimat® is NOT a suitable alternative to the HandiHaler® during the manufacturing problem. The Respimat® continues to be only approved for use by the respiratory team.

[Click Here](#) to access chapter 3.1 (Bronchodilators) of the Tayside Area Formulary.



Drug Safety Updates

Please follow link - [Volume 7, Issue 4, November 2013](#)

Please follow link - [Volume 7, Issue 5, December 2013](#)



[illegible]

Medicine	Indication	Local recommendation category	Comments and useful links
Ranibizumab, 10mg/mL, solution for injection (Lucentis®) (907/13) - Full submission	Treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults.	Hospital Only Ophthalmology Specialist List 1st line Supplied via a Patient Access Scheme	SMC advice SPC link
Sodium phenylbutyrate granules 483mg/g (Pheburane®) (914/13) - Abbreviated submission	Adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.	GP under the direction of specialist in metabolic disorders	SMC advice

'Local processes exist to allow consideration of prescribing outwith SMC advice or outwith NHS Tayside formulary. Details are available in the [NHS Tayside Policy on the Prescribing of Medicines that are Non-formulary \(including Individual Patient Treatment Requests\)](#)'

* 'pending' means that no local recommendation to support use is in place at the current time

Updates from previous SMC Advice

Medicine	Indication	Local recommendation category	Comments and useful links
Bimatoprost 0.3mg/mL plus timolol 5mg/mL, preservative-free, single-dose eye-drops (Ganfort® Unit Dose Preservative Free) (906/13) - Abbreviated submission	For the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical betablockers or prostaglandin analogues. SMC restriction: to use in patients who have proven sensitivity to preservatives.	GP under direction of Ophthalmology Ophthalmology Specialist List Restricted to use in patients who cannot tolerate preservative	SMC advice SPC link <i>Considerably more expensive than latanoprost & timolol plus preservative</i>
Nalmefene 18mg film-coated tablets (Selincro®) (917/13) - Full submission	The reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.	Non-Formulary - protocol pending	SMC advice SPC link

'Local processes exist to allow consideration of prescribing outwith SMC advice or outwith NHS Tayside formulary. Details are available in the [NHS Tayside Policy on the Prescribing of Medicines that are Non-formulary \(including Individual Patient Treatment Requests\)](#)'

TAF Section	Drug(s)/topic	Changes
Specialist formulary lists and formulary development	Parkinson's disease	Parkinson's disease specialist formulary list added.
4.6 (netFormulary only)*	Drugs used in nausea and vertigo	Ondansetron orodispersible films (Setofilm®) added to formulary for haematology or oncology patients who cannot take any other oral forms of ondansetron due to enhanced risk of aspiration or swallowing difficulties.
4.6 (netFormulary only)* Parkinson's disease specialist formulary list	Domperidone	Indication for postural hypotension associated with dopamine agonists (particularly apomorphine) [off-label] added to Medicines for the Elderly (MFE) and Parkinson's disease specialist list (under specialist direction).
4.9.1 (net Formulary only)* Parkinson's disease specialist formulary list	Dopaminergic drugs used in Parkinson's disease	Apomorphine and amantadine added to formulary (under specialist direction) and Parkinson's disease specialist list. All dopaminergic drugs used in Parkinson's disease classified as 'Amber' (GPs may prescribe under specialist direction).
4.9.2 (netFormulary only)* Parkinson's disease specialist formulary list	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl hydrochloride (benzhexol) added to formulary (under specialist direction) and Parkinson's disease specialist list.
11.6 Ophthalmology specialist list	Prostaglandin analogues	Bimatoprost with timolol single-dose eye drops added to formulary (under specialist direction) and Ophthalmology specialist list, restricted to patients who require both components and who cannot tolerate preservative. Bimatoprost with timolol standard eye drops are non-formulary.
11.8.2 Ophthalmology specialist list	Ocular diagnostic, peri-operative preparations and photodynamic treatment	Ranibizumab, 10mg/mL, solution for injection (Lucentis®) added to formulary (Hospital Only) and Ophthalmology specialist list.

* Tayside netFormulary currently under development and not available for open access.



SMC Briefing Note:

[Click here](#) for November Briefing Note

Forthcoming SMC Advice

This bulletin is produced by the Medicines Advisory Group (MAG), which is a sub-group of the NHS Tayside Drug and Therapeutics Committee.

Please direct any queries to either:

Karen Harkness
Principal Pharmacist - Clinical Effectiveness
email: kharkness@nhs.net

or

Claire James
Senior Pharmacist - Clinical Effectiveness
email: clairejames@nhs.net

Local implementation of SMC recommendations is taken forward by the Tayside Medicines Governance Unit. This bulletin is based on evidence available to the Tayside Medicines Governance Unit at time of publication and is covered by the Disclaimer and Terms & Conditions of use.

[CLICK HERE](#) for access to the Medicines Governance section of the Pharmacy Staffnet site.